Premium
Clinical Efficacy of Eprosartan
Author(s) -
Weber Michael
Publication year - 1999
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.19.7.95s.30950
Subject(s) - blood pressure , medicine , placebo , angiotensin ii receptor type 1 , angiotensin ii , adverse effect , antagonist , pharmacology , oral administration , angiotensin ii receptor antagonist , orally active , candesartan , angiotensin receptor , clinical trial , receptor , alternative medicine , pathology
Eprosartan is a new, structurally distinct, nonbiphenyl, nontetrazole, nonpeptide, orally active angiotensin II receptor antagonist that is highly selective for the AT 1 receptor. In placebo‐controlled trials, it led to a dose‐related antihypertensive response, clinically significant reductions in blood pressure and full 24‐hour blood pressure control with once/day administration of 600 mg. Eprosartan provides clinically significant reductions in blood pressure in patients with mild to severe hypertension regardless of age, gender, and race. The antihypertensive effect of eprosartan is comparable with those of other antihypertensive agents. Whereas a relationship exists between dosage and antihypertensive effect, there is no such relationship between dosage and adverse events, the frequency of which is comparable with that with placebo.